CMS Unconvinced On PET Scans For Bone Metastasis; CED Data Not Enough
This article was originally published in The Gray Sheet
While National Oncologic PET Registry data has been effective in persuading CMS to remove evidence-development restrictions from positron emission tomography coverage policies in the past, NOPR data was not enough to support coverage of PET scans to identify bone metastasis in a Dec. 15 national coverage determination.
You may also be interested in...
In a final decision memo released June 11, the Medicare agency provides national coverage for three post-cancer-treatment PET scans. The original coverage proposal would have allowed only one.
The May 8 commencement of a nationwide positron emission tomography imaging registry is an important step forward for CMS' fledgling coverage-with-evidence-development (CED) policy, not to mention for expanded use of PET scans
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.